Legal & General Group
EDIT icon

Legal & General Group’s Editas Medicine EDIT Stock Holding History

Legal & General Group’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$19.3K Hold
7,778
– – ﹤0.01% 2975
2025
Q4 		$15.9K Hold
7,778
– – ﹤0.01% 3113
2025
Q3 		$27K Hold
7,778
– – ﹤0.01% 2923
2025
Q2 		$17.1K Sell
7,778
-7,462
-49% -$12.2K ﹤0.01% 3074
2025
Q1 		$17.7K Hold
15,240
– – ﹤0.01% 2982
2024
Q4 		$19.4K Sell
15,240
-68,559
-82% -$175K ﹤0.01% 3038
2024
Q3 		$286K Buy
83,799
+4,371
+6% +$19K ﹤0.01% 2618
2024
Q2 		$371K Hold
79,428
– – ﹤0.01% 2527
2024
Q1 		$589K Buy
79,428
+1,807
+2% +$15K ﹤0.01% 2366
2023
Q4 		$786K Sell
77,621
-145
-0.2% -$1.27K ﹤0.01% 2282
2023
Q3 		$607K Buy
77,766
+8,203
+12% +$70.3K ﹤0.01% 2358
2023
Q2 		$573K Sell
69,563
-100,558
-59% -$876K ﹤0.01% 2420
2023
Q1 		$1.23M Buy
170,121
+15,062
+10% +$134K ﹤0.01% 2082
2022
Q4 		$1.38M Buy
155,059
+93,750
+153% +$1.03M ﹤0.01% 2037
2022
Q3 		$750K Sell
61,309
-96,794
-61% -$1.51M ﹤0.01% 2234
2022
Q2 		$1.87M Buy
158,103
+27,835
+21% +$373K ﹤0.01% 1918
2022
Q1 		$2.48M Buy
130,268
+17,939
+16% +$333K ﹤0.01% 1895
2021
Q4 		$2.98M Buy
112,329
+29,809
+36% +$1.03M ﹤0.01% 1840
2021
Q3 		$3.39M Sell
82,520
-50,891
-38% -$2.79M ﹤0.01% 1747
2021
Q2 		$7.56M Buy
133,411
+14,905
+13% +$551K ﹤0.01% 1329
2021
Q1 		$4.98M Buy
118,506
+36,069
+44% +$2.05M ﹤0.01% 1554
2020
Q4 		$5.78M Buy
82,437
+36,033
+78% +$1.48M ﹤0.01% 1400
2020
Q3 		$1.3M Buy
46,404
+1,140
+3% +$37.1K ﹤0.01% 1943
2020
Q2 		$1.34M Buy
45,264
+9,491
+27% +$248K ﹤0.01% 1890
2020
Q1 		$746K Buy
35,773
+1,091
+3% +$27.5K ﹤0.01% 1943
2019
Q4 		$1.03M Buy
34,682
+2,315
+7% +$57.8K ﹤0.01% 2060
2019
Q3 		$735K Buy
32,367
+11,452
+55% +$284K ﹤0.01% 2084
2019
Q2 		$518K Buy
20,915
+2,510
+14% +$59.9K ﹤0.01% 2138
2019
Q1 		$450K Buy
18,405
+228
+1% +$5.16K ﹤0.01% 2178
2018
Q4 		$413K Buy
18,177
+886
+5% +$24.1K ﹤0.01% 2158
2018
Q3 		$551K Buy
17,291
+10,065
+139% +$325K ﹤0.01% 2116
2018
Q2 		$259K Buy
7,226
+231
+3% +$8.18K ﹤0.01% 2250
2018
Q1 		$232K Sell
6,995
-1,216
-15% -$43.3K ﹤0.01% 2269
2017
Q4 		$254K Sell
8,211
-245
-3% -$6.17K ﹤0.01% 2247
2017
Q3 		$201K Sell
8,456
-198
-2% -$3.77K ﹤0.01% 2342
2017
Q2 		$145K Buy
8,654
+6,535
+308% +$118K ﹤0.01% 2424
2017
Q1 		$47K Sell
2,119
-162
-7% -$3.36K ﹤0.01% 2885
2016
Q4 		$37K Buy
2,281
+1,227
+116% +$18.6K ﹤0.01% 2954
2016
Q3 		$14K Hold
1,054
– – ﹤0.01% 2836
2016
Q2 		$26K Buy
+1,054
New +$35.6K ﹤0.01% 2793

Other funds holding EDIT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Legal & General Group's EDIT Position: Q1 2026 in Review

Legal & General Group held its Editas Medicine (EDIT) position steady in Q1 2026 at 7,778 shares worth $19.3K. The position accounts for ﹤0.01% of the portfolio, ranked #2975.

Legal & General Group first reported a position in EDIT in Q2 2016 and has held it in 40 quarters since. The position peaked at $7.56M in Q2 2021. 207 funds tracked by Wall St. Rank hold EDIT as of Q1 2026.

  • Legal & General Group held 7,778 shares of Editas Medicine worth $19.3K as of Q1 2026.
  • Legal & General Group left its Editas Medicine share count unchanged in Q1 2026.
  • Editas Medicine made up ﹤0.01% of Legal & General Group's portfolio in Q1 2026, its #2975 holding.
  • Legal & General Group first reported a position in Editas Medicine in Q2 2016 and has held it in 40 quarters since.
  • Legal & General Group's Editas Medicine position peaked at $7.56M in Q2 2021.
  • 207 funds tracked by Wall St. Rank held Editas Medicine as of Q1 2026.

Based on Legal & General Group's 13F filing for Q1 2026, filed 8 May 2026.